
GLP-1 and Thiazolidinediones May Lower Heart Risk in T2D
TOPLINE: In patients with type 2 diabetes (T2D), combination therapy with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and thiazolidinediones was associated with a reduced risk for all-cause mortality, cardiovascular mortality, and major adverse …